This continuing medical education activity is provided by Vindico Medical Education
This educational activity is supported by an educational grant from Durata Therapeutics, Inc.
The intended audience for the activity is emergency medicine physicians, hospitalists and other health care professionals involved in the treatment of patients with acute bacterial skin and skin structure infections.
At the conclusion of this video series participants should be able to:
Patients with acute bacterial skin and skin structure infections (ABSSSI) commonly present to emergency departments (EDs) in the US. The severity of these infections ranges from mild cellulitis to serious life-threatening necrotizing infections, and their leading identifiable cause is community-acquired methicillin-resistant Staphylococcus aureus (MRSA). The incidence of ABSSSI and ABSSSI-related hospitalizations is increasing (annual number of ED visits related to these infections has nearly tripled between 1993 and 2005 alone), a rise that correlates with an escalation of MRSA infections.
The increasing prevalence of MRSA prompted the Infectious Diseases Society of America (IDSA) to update their practice guidelines for the diagnosis and management of ABSSSI in 2014. However, clinicians’ adherence to guidelines remains somehow inconsistent. This may lead to suboptimal outcomes for patients, as well as increased risk of resistant bacteria emergence and health care costs.
Vancomycin is currently the drug of choice against resistant Gram-positive cocci; yet, resistance to this agent has appeared in both enterococci and S. aureus, resulting in decreased efficacy. The emergence of vancomycin-intermediate S. aureus (VISA), vancomycin-heteroresistant S. aureus (hVISA) and vancomycin-resistant S. aureus (VRSA) has led to concerns that clinical failures may be associated with gradual loss of vancomycin activity. This scenario reflects an unmet need for new compounds that are more effective against MRSA and other multi-drug resistant gram-positive organisms. Dalbavancin and oritavancin are 2 promising, recently approved intravenous antibiotics for the treatment of ABSSSI with a similar spectrum of activity, improved activity against vancomycin-resistant strains, lower likelihood of inducing resistance, and an extended half-life that allows to treat patients who might otherwise require hospitalization in an outpatient basis.
In this CME activity, David A. Talan, MD (Professor Emeritus, Department of Emergency Medicine/Internal Medicine, David Geffen School of Medicine at UCLA) will address current IDSA guidelines for diagnosis and treatment of ABSSSI, and discuss challenges associated with its management, new diagnostic technologies, main causes for treatment failure, as well as benefits of recently approved antibiotics.
David A. Talan, MD
The David Geffen School of Medicine at UCLA
Department of Emergency Medicine/Internal Medicine, Division of Infectious Diseases
Olive View-UCLA Medical Center
Los Angeles, CA
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ (0.25 credits per video). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release: October 23, 2014 to October 22, 2015.
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 2 OR 100% of the post-test questions correctly for each video. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
David A. Talan, MD
F. Perry Wilson, MD, MSCE
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
2014 Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact us at firstname.lastname@example.org